SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced the publication of in vitro data highlighting the antibacterial activity of prulifloxacin in the March 2009 edition of Antimicrobial Agents and Chemotherapy published by the American Society for Microbiology. The article is titled, “Antimicrobial Activity of Prulifloxacin Tested against a Worldwide Collection of Gastroenteritis-Producing Pathogens, Including Those Causing Traveler’s Diarrhea” (AAC March 2009; v.53: 1221-1224). The results from these studies compared the in vitro antibacterial activity of prulifloxacin to that of other antimicrobial agents against 582 strains from global surveillance studies, including Escherichia coli, Salmonella spp., Shigella spp., Yersinia spp., Vibrio spp., Aeromonas spp., Plesiomonas spp., and Campylobacter spp. The study was conducted by JMI Laboratories and demonstrated that prulifloxacin is the most active of the antimicrobial agents tested against these gastroenteritis-causing pathogens.
